Affiliation: | 1.Sleep Disorders Center, Division of Pulmonary and Critical Care Medicine,University of Maryland School of Medicine,Baltimore,USA;2.Veterans Affairs Oxnard Clinic,Oxnard,USA;3.Pharmaceutical Health Services Research Department,University of Maryland School of Pharmacy,Baltimore,USA |
Abstract: | BackgroundObstructive sleep apnea (OSA) is a common underdiagnosed sleep disorder. Various strategies have been employed to easily screen for OSA. The ApneaStrip® (AS - S.L.P. Ltd, Tel Aviv, Israel) is an FDA approved OSA screening device applied to the upper lip at home. We evaluated the performance of this device against simultaneous in-laboratory polysomnography (PSG) in a group of well-characterized OSA patients.MethodsDiagnostic PSG was performed in 56 patients (29 M, 37 F; age 48.9?±?14.6 years; body mass index [BMI] 37.5?±?9.0 kg/m2; apnea-hypopnea index—events/h—[AHI] 32.8?±?22.9). The AS was applied and positioned to detect nasal and oral airflow. The AS gives a “positive” result for AHI?≥?15. We examined the sensitivity and specificity of the AS against three thresholds derived from PSG: AHI?≥?5, AHI?≥?15 (company recommendation), and AHI?≥?30.ResultsFor PSG AHI?≥?15, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the AS were 80, 54.5, 87.8, and 40 %, respectively. For PSG AHI?≥?5, the values were 75.1, 66.7, 97.1, and 13.3 %, respectively. For PSG AHI?≥?30, the values were 86.9, 36.2, 48.8, and 80 %, respectively. There were no significant modifying effects of age, BMI, gender, hypertension, diabetes, lung disease, and heart disease.ConclusionThe AS has a high sensitivity for detection of OSA with AHI?≥?15, but only modest specificity. The AS could be a useful component of an OSA screening program; however, negative results should be interpreted cautiously. |